All In Biotech

Drug Trial Radar · NCT05670730

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping

A Phase 1/2, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single and Multiple Ascending Doses of AOC 1044 Administered Intravenously to Healthy Adult Volunteers and Participants With DMD Mutations Amenable to Exon 44 Skipping

Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Nov 9, 2022

Primary completion

Nov 25, 2024

Study completion Nov 25, 2024

Sponsor

Lead sponsor
Avidity Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jan 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 7 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping. Part A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers. Part B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.

Conditions

  • Duchenne Muscular Dystrophy
  • Exon 44

Interventions

  • AOC 1044Drug

    AOC 1044 will be administered via intravenous (IV) infusion

  • PlaceboDrug

    Placebo will be administered via intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: Through study completion, up to Day 85 (Part A) or Day 169 (Part B)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's

    Little Rock, Arkansas

  • UCSD

    La Jolla, California

  • Stanford University

    Palo Alto, California

  • Rare Disease Research - Atlanta

    Atlanta, Georgia

  • University of Iowa

    Iowa City, Iowa

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts

  • Gillette Children's

    Saint Paul, Minnesota

  • Rare Disease Research NC

    Hillsborough, North Carolina

  • Abigail Research Institute at Nationwide Children's Hospital

    Columbus, Ohio

  • Worldwide Clinical Trials (Part A only)

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.